基蛋生物收盘上涨1.14%，滚动市盈率22.25倍，总市值44.93亿元

Core Viewpoint - The company,基蛋生物, is experiencing a decline in its financial performance, with significant drops in revenue and net profit, while its stock valuation remains low compared to the industry average. Company Summary - 基蛋生物's closing stock price on August 4 was 8.86 yuan, up 1.14%, with a rolling PE ratio of 22.25, marking a new low in 154 days, and a total market capitalization of 4.493 billion yuan [1] - The company specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, particularly in the POCT field, and is recognized as a key high-tech enterprise under the National Torch Program [1] - The latest quarterly report for Q1 2025 shows a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross profit margin of 77.15% [1] Industry Summary - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, positioning 基蛋生物 at 49th place within the industry [2] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation [2] - The total number of shareholders as of March 31, 2025, is 26,747, a decrease of 451, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]